NAMkind Liver
NAMkind Intestinal models (GI)
NAMkind Liver
Our DILI prediction service is built on a scientifically validated liver model, tested against 61 FDA-recommended compounds as part of the NAMs roadmap. Using primary cells from healthy donors, we offer flexible set up sizes—from 4 to 160 compounds ( >160 compounds run in multiple batches)—depending on dose-response requirements. Each study generates 48 to 480 data points per biomarker, covering four key indicators of liver health: ATP (tissue viability), LDH (cytotoxicity), GSH (oxidative stress), and albumin (hepatocyte-specific function). With a standard turnaround time of approximately 4 weeks, we provide reliable, data-driven insights to support safer and more informed drug development decisions.
NAMkind Intestinal models (GI)
Our GI toxicity prediction service is based on a validated intestinal model tested with 42 reference drugs, ensuring reliable performance for early safety assessment. Using primary cells from healthy donors, we offer flexible batch sizes ranging from 2 to 108 compounds, generating 48 to 648 data points per biomarker(>108 compounds run in multiple batches). The platform measures three key indicators of gastrointestinal health: TEER (mucosal barrier integrity), ATP (tissue viability), and Alamar Blue (oxidative stress). This model currently predicts diarrhea risk, providing actionable insights to support safer drug development. Standard turnaround time for a study of this scale is one month.
